Modified 5‐aminolevulinic acid photodynamic therapy reduces pain and improves therapeutic effects in cutaneous squamous cell carcinoma mouse model
- 23 January 2022
- journal article
- research article
- Published by Wiley in Lasers in Surgery and Medicine
- Vol. 54 (5) , 804-812
Abstract
Background and Objectives: Conventional ALA‐PDT (C‐PDT) has limited efficacy in cutaneous squamous cell carcinoma (cSCC), and there is obvious pain during treatment, which limits its clinical application. We sought to modify photodynamic therapy into a more painless and effective treatment.Methods: We modified C‐PDT by reducing the incubation time of the pro‐sensitizer and increasing the light dose; we named this method modified ALA‐PDT (M‐PDT). We compared the pain response and curative effect between C‐PDT and M‐PDT in cSCC mouse models. Pain‐related proteins were examined by western blot analysis and immunohistochemistry. Tumor progression‐associated signaling pathways were analyzed by RNA‐seq and western blot analysis. Reactive oxygen species (ROS) generation was measured with a ROS test kit and Microplate reader.Results: M‐PDT greatly reduced pain during treatment. Interestingly, when the cSCC tumor volume increased to 150–200 mm3, M‐PDT almost completely eliminated the tumors, while C‐PDT did not. The better curative effect of M‐PDT might be due to the stronger suppression of the Stat3, Erk1/2, and mTOR signaling pathways. Moreover, flow cytometry demonstrated that M‐PDT could recruit CD8+ T cells to inhibit cSCC progression. Further investigation determined that the different mechanisms of C‐PDT and M‐PDT were related to more ROS generation induced by M‐PDT.Conclusions: Our results suggest that M‐PDT, which is more painless and effective than C‐PDT, is expected to provide a solution for the treatment of cSCC.Keywords
Funding Information
- National Natural Science Foundation of China (82073013, 31801187)
- Natural Science Foundation of Shanghai Municipality (21ZR1457100)
This publication has 37 references indexed in Scilit:
- European guidelines for topical PDT part 1 JEADV 2013; 27: 536–544Journal of the European Academy of Dermatology and Venereology, 2013
- Daylight photodynamic therapy for actinic keratosis: an international consensusJournal of the European Academy of Dermatology and Venereology, 2011
- The impact of different fluence rates on pain and clinical outcome in patients with actinic keratoses treated with photodynamic therapyPhotodermatology, Photoimmunology & Photomedicine, 2011
- Pain during topical photodynamic therapy: uncomfortable and unpredictableJournal of the European Academy of Dermatology and Venereology, 2010
- Imaging and Photodynamic Therapy: Mechanisms, Monitoring, and OptimizationChemical Reviews, 2010
- Impact of Central and Peripheral TRPV1 and ROS Levels on Proinflammatory Mediators and Nociceptive BehaviorMolecular Pain, 2010
- Pain associated with aminolevulinic acid-photodynamic therapy of skin diseaseJournal of the American Academy of Dermatology, 2009
- Treatment of skin cancer and pre-cancer using topical ALA-PDT—A single hospital experiencePhotodiagnosis and Photodynamic Therapy, 2008
- Photodynamic therapy of cutaneous epithelial malignanciesDie Dermatologie, 2007
- Protease-Activated Receptor 2 Sensitizes the Capsaicin Receptor Transient Receptor Potential Vanilloid Receptor 1 to Induce HyperalgesiaJournal of Neuroscience, 2004